EUCTR2021-001509-66-NL进行中（未招募）1 期
rEaL-world pharmacokinetics of Immune Checkpoint InhibiTors (ELICIT) - ELICIT
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Treatment with the ICIs mentioned in paragraph 4.1
- •- Willingness and ability to provide written IC
- •- Age 18 years or older
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 70
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 70
排除标准
- •Since we aim to assess the real-world pharmacokinetics, we will not make use of any exclusion criteria.
研究者
相似试验
招募中
4 期
rEaL-world pharmacokinetics of Immune Checkpoint InhibiTors (ELICIT)10038666NSCLClung cancerNL-OMON51955Radboud Universitair Medisch Centrum100
终止
不适用
Real World Pharmacokinetics of Immune Checkpoint InhibitorsCancerNCT04833075Radboud University Medical Center19
招募中
Unknown
A real-world study of efficacy and safety of Immune check point inhibitors in patients with non-small cell lung cancer harboring driver oncogene excepting EGFRJPRN-UMIN000049022orth East Japan Study Group870
招募中
不适用
Predictive biomarker study of immune checkpoint inhibitors in metastatic head and neck squamous cell carcinomaNeoplasmsKCT0007598ational Cancer Center50
招募中
不适用
Real-world Efficacy and Safety of Immune check point inhibitors for Refractory Head and Neck Cancer: A Retrospective Multicenter StudyNeoplasmsKCT0004258Chung-Ang Univerisity Hospital100